Skip to main content

INVOKANA

NDC 50458-141 · Janssen Pharmaceuticals, Inc.

Generic namecanagliflozin
Dosage formTABLET, FILM COATED
RouteORAL
Active ingredient(s)CANAGLIFLOZIN
Strength300 mg/1
Pharmacologic classP-Glycoprotein Inhibitors [MoA], Sodium-Glucose Cotransporter 2 Inhibitor [EPC], Sodium-Glucose Transporter 2 Inhibitors [MoA]
Marketing categoryNDA

Packages

50458-141-01 — 5 TABLET, FILM COATED in 1 BOTTLE (50458-141-01)

50458-141-10 — 10 BLISTER PACK in 1 CARTON (50458-141-10) / 10 TABLET, FILM COATED in 1 BLISTER PACK

50458-141-30 — 30 TABLET, FILM COATED in 1 BOTTLE (50458-141-30)

50458-141-50 — 500 TABLET, FILM COATED in 1 BOTTLE (50458-141-50)

50458-141-90 — 90 TABLET, FILM COATED in 1 BOTTLE (50458-141-90)

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

50090-4364 — canagliflozin, 50090-5034 — canagliflozin, 50458-140 — canagliflozin, 50458-540 — canagliflozin and metformin hydrochloride, 50458-541 — canagliflozin and metformin hydrochloride, 50458-542 — canagliflozin and metformin hydrochloride, 50458-543 — canagliflozin and metformin hydrochloride, 50458-940 — canagliflozin and metformin hydrochloride, 50458-941 — canagliflozin and metformin hydrochloride, 50458-942 — canagliflozin and metformin hydrochloride, 50458-943 — canagliflozin and metformin hydrochloride, 55154-1425 — canagliflozin, 55154-1426 — canagliflozin

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.

Read from: FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24; CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q3 (July 2026 release). All data sources · How to read the labels